Intra-Cellular Therapies (ITCI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ITCI Intra-Cellular Therapies

Watchlist

64.760
-1.120-1.70%

Close Apr 15 16:00 ET

6.27BMarket Cap-44356P/E (TTM)

Pre-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
TipRanksApr 5 07:00 ET
Intra-Cellular Therapies Buy Rating: High Confidence in Caplyta's Success for MDD Treatment
TipRanksApr 5 05:25 ET
Express News | Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target
Moomoo 24/7Apr 5 05:15 ET
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
BenzingaApr 4 13:35 ET
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
During the last three months, 8 analysts shared their evaluations of Intra-Cellular Therapies (NASDAQ:ITCI), revealing diverse outlooks from bullish to bearish.The following table encapsulates their r
BenzingaApr 3 10:01 ET
RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price Target
RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies with a Outperform and maintains $86 price target.
Analyst UpgradesApr 3 08:52 ET

Comments

Meltyy

Apr 1 15:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$Hutchmed (China)(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...

Moomoo AI

Mar 27 23:03

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Meltyy

Mar 22 10:48

Mental Health Biotech Catalyst Watchlist

$Vanda Pharmaceuticals(VNDA.US)$ PDUFA
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$Bristol-Myers Squibb(BMY.US)$ PDUFA
$Alzamend Neuro(ALZN.US)$ Phase 2
$Alzamend Neuro(ALZN.US)$ Phase 2a

Meltyy

Feb 22 12:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...

Moomoo AI

Feb 14 22:15

The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.